These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 30858207)

  • 1. Evaluation of the Bactericidal Activity of Fosfomycin in Combination with Selected Antimicrobial Comparison Agents Tested against Gram-Negative Bacterial Strains by Using Time-Kill Curves.
    Flamm RK; Rhomberg PR; Lindley JM; Sweeney K; Ellis-Grosse EJ; Shortridge D
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of In vitro Efficacy of Meropenem/Colistin and Meropenem/Fosfomycin Combinations on Multidrug Resistant Gram-Negative Bacilli].
    Adaleti R; Nakipoğlu Y; Arıcı N; Kansak N; Çalık Ş; Şenbayrak S; Balık R; Aksaray S
    Mikrobiyol Bul; 2023 Jul; 57(3):365-377. PubMed ID: 37462301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility of multiresistant gram-negative bacteria to fosfomycin and performance of different susceptibility testing methods.
    Perdigão-Neto LV; Oliveira MS; Rizek CF; Carrilho CM; Costa SF; Levin AS
    Antimicrob Agents Chemother; 2014; 58(3):1763-7. PubMed ID: 24323469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates.
    Vidaillac C; Benichou L; Duval RE
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4856-61. PubMed ID: 22751540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation effects of amikacin and fosfomycin against selected amikacin-nonsusceptible Gram-negative respiratory tract pathogens.
    Montgomery AB; Rhomberg PR; Abuan T; Walters KA; Flamm RK
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3714-9. PubMed ID: 24752275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria.
    Kastoris AC; Rafailidis PI; Vouloumanou EK; Gkegkes ID; Falagas ME
    Eur J Clin Pharmacol; 2010 Apr; 66(4):359-68. PubMed ID: 20186407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development.
    Souli M; Galani I; Boukovalas S; Gourgoulis MG; Chryssouli Z; Kanellakopoulou K; Panagea T; Giamarellou H
    Antimicrob Agents Chemother; 2011 May; 55(5):2395-7. PubMed ID: 21321144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Fosfomycin Resistance Protein FosA by Phosphonoformate (Foscarnet) in Multidrug-Resistant Gram-Negative Pathogens.
    Ito R; Tomich AD; McElheny CL; Mettus RT; Sluis-Cremer N; Doi Y
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
    Rodríguez-Avial I; Pena I; Picazo JJ; Rodríguez-Avial C; Culebras E
    Int J Antimicrob Agents; 2015 Dec; 46(6):616-21. PubMed ID: 26391381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of synergy between sulbactam, meropenem and colistin in carbapenem-resistant Klebsiella pneumoniae and Acinetobacter baumannii isolates and correlation with the molecular mechanism of resistance.
    Laishram S; Anandan S; Devi BY; Elakkiya M; Priyanka B; Bhuvaneshwari T; Peter JV; Subramani K; Balaji V
    J Chemother; 2016 Aug; 28(4):297-303. PubMed ID: 27461479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fosfomycin in severe infections due to genetically distinct pan-drug-resistant Gram-negative microorganisms: synergy with meropenem.
    Perdigão Neto LV; Oliveira MS; Martins RCR; Marchi AP; Gaudereto JJ; da Costa LATJ; de Lima LFA; Takeda CFV; Costa SF; Levin AS
    J Antimicrob Chemother; 2019 Jan; 74(1):177-181. PubMed ID: 30376073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic activity profile of an antimicrobial peptide against multidrug-resistant and extensively drug-resistant strains of Gram-negative bacterial pathogens.
    Pollini S; Brunetti J; Sennati S; Rossolini GM; Bracci L; Pini A; Falciani C
    J Pept Sci; 2017 Apr; 23(4):329-333. PubMed ID: 28176481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Do different interpretative methods used for evaluation of checkerboard synergy test affect the results?].
    Ozseven AG; Sesli Çetin E; Ozseven L
    Mikrobiyol Bul; 2012 Jul; 46(3):410-20. PubMed ID: 22951653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-wall-inhibiting antibiotic combinations with activity against multidrug-resistant Klebsiella pneumoniae and Escherichia coli.
    Hickman RA; Hughes D; Cars T; Malmberg C; Cars O
    Clin Microbiol Infect; 2014 Apr; 20(4):O267-73. PubMed ID: 24118201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High susceptibility of MDR and XDR Gram-negative pathogens to biphenyl-diacetylene-based difluoromethyl-allo-threonyl-hydroxamate LpxC inhibitors.
    Titecat M; Liang X; Lee CJ; Charlet A; Hocquet D; Lambert T; Pagès JM; Courcol R; Sebbane F; Toone EJ; Zhou P; Lemaitre N
    J Antimicrob Chemother; 2016 Oct; 71(10):2874-82. PubMed ID: 27330072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey.
    Demir T; Buyukguclu T
    Int J Infect Dis; 2013 Nov; 17(11):e966-70. PubMed ID: 23742831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergy of fosfomycin with beta-lactam antibiotics against staphylococci and aerobic gram-negative bacilli.
    Chin NX; Neu NM; Neu HC
    Drugs Exp Clin Res; 1986; 12(12):943-7. PubMed ID: 3569007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From Breast Cancer to Antimicrobial: Combating Extremely Resistant Gram-Negative "Superbugs" Using Novel Combinations of Polymyxin B with Selective Estrogen Receptor Modulators.
    Hussein MH; Schneider EK; Elliott AG; Han M; Reyes-Ortega F; Morris F; Blastovich MAT; Jasim R; Currie B; Mayo M; Baker M; Cooper MA; Li J; Velkov T
    Microb Drug Resist; 2017 Jul; 23(5):640-650. PubMed ID: 27935770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergy Testing by E-Test and Microdilution Checkerboard for Fosfomycin Combined with Tigecycline against KPC-Producing Klebsiella pneumoniae.
    Huang L; Wang M; Sun L
    Clin Lab; 2019 Dec; 65(12):. PubMed ID: 31850708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance.
    Ku YH; Chen CC; Lee MF; Chuang YC; Tang HJ; Yu WL
    J Microbiol Immunol Infect; 2017 Dec; 50(6):931-939. PubMed ID: 28716360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.